Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Illinois National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00416325 |
RATIONALE: Chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. The use of lycopene, a substance found in tomatoes, may keep prostate cancer from forming in patients at high risk of developing prostate cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of lycopene in preventing prostate cancer in patients who are at high risk of developing prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Dietary Supplement: lycopene Other: laboratory biomarker analysis |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention |
Official Title: | Phase I Multiple Dose Pharmacokinetic Study of Lycopene Delivered in a Well-Defined Food-Based Lycopene Delivery System (Tomato Paste-Oil Mixture) in Patients at Increased Risk for Developing Prostate Cancer |
Estimated Enrollment: | 18 |
OBJECTIVES:
Characterize surrogate endpoint biomarkers (SEBs) in the peripheral blood, buccal mucosa, and the prostate itself, which will provide evidence of biological activity relevant to a chemoprevention effect.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive oral lycopene in tomato paste and olive oil, once, twice, or three times daily for 3 months.
Cohorts of 6 patients receive escalating doses of lycopene until the maximum tolerated dose (MTD) is determined.
The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Patients undergo buccal scrapings and blood collection periodically during study for pharmacokinetics and biomarker studies.
After completion of study treatment, patients are followed for 1 month.
PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.
Ages Eligible for Study: | 35 Years to 75 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Elevated prostate-specific antigen (PSA), meeting 1 of the following criteria:
Has undergone a prostate biopsy* (following findings of elevated PSA) within the past 180 days that failed to reveal prostate cancer
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Study ID Numbers: | CDR0000467322, UIC-2000-0931 |
Study First Received: | December 27, 2006 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00416325 History of Changes |
Health Authority: | United States: Federal Government |
prostate cancer |
Anticarcinogenic Agents Radiation-Protective Agents Antioxidants Prostatic Diseases Genital Neoplasms, Male |
Lycopene Urogenital Neoplasms Tomato Genital Diseases, Male Prostatic Neoplasms |
Anticarcinogenic Agents Radiation-Protective Agents Antioxidants Genital Neoplasms, Male Prostatic Diseases Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Lycopene Physiological Effects of Drugs |
Urogenital Neoplasms Genital Diseases, Male Protective Agents Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Prostatic Neoplasms |